Masoprocol - GlaxoSmithKline

Drug Profile

Masoprocol - GlaxoSmithKline

Alternative Names: Actinex; CHX 100; meso-NDGA; SP 134101

Latest Information Update: 11 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Access Pharmaceuticals
  • Developer Abeona Therapeutics; Access Pharmaceuticals; GlaxoSmithKline
  • Class Anti-inflammatories; Catechols; Lignans; Small molecules
  • Mechanism of Action Lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis
  • Discontinued Cancer; Photodamage

Most Recent Events

  • 05 Dec 2001 Discontinued-Clinical for Photodamage in USA (Topical)
  • 05 Dec 2001 Discontinued-Preclinical for Cancer in USA (PO)
  • 05 Dec 2001 No-Development-Reported for Actinic keratosis in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top